Wnt/β-catenin pathway in bone cancers

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9439-9445

  Tian, Jian ^a   He, Hongbo ^a   Lei, Guanghua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Beta catenin; Chondroma; Chondrosarcoma; Ewing s sarcoma; Osteosarcoma; Wnt pathway

Indexed keywords

BETA CATENIN; CELECOXIB; DICKKOPF 1 PROTEIN; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3BETA; ICARIIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LYMPHOID ENHANCER FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE P38; ORIDONIN; SMALL INTERFERING RNA; WNT PROTEIN; WNT3A PROTEIN;

ANEMIA; BONE METASTASIS; BONE PAIN; BONE SWELLING; CARCINOGENESIS; CARTILAGE CELL; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHONDROMA; CHONDROSARCOMA; CHONDROSARCOMA CELL LINE; CHROMOSOME TRANSLOCATION; DOWN REGULATION; ENZYME PHOSPHORYLATION; EWING SARCOMA; EWING SARCOMA CELL LINE; FEVER; GENE EXPRESSION; GENE SILENCING; HUMAN; HYALINE CARTILAGE; METASTASIS POTENTIAL; NERVE FIBER GROWTH; NOSE OBSTRUCTION; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; RABDOSIA; RABDOSIA RUBESCENS; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BONE TUMOR; METABOLISM; PHYSIOLOGY;

ANIMALS; BONE NEOPLASMS; HUMANS; SIGNAL TRANSDUCTION;

EID: 84921053930     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2433-8     Document Type: Review

References (61)

1. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9–26.
2. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008;4:68–75.
3. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8:387–98.
4. Rao TP, Kühl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res. 2010;106:1798–806.
5. Mao J, Wang J, Liu B, Pan W, Farr 3rd GH, Flynn C, et al. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell. 2001;7:801–9.
6. Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, et al. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development. 2008;135:367–75.
7. He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development. 2004;131:1663–77.
8. Sakanaka C, Sun TQ, Williams LT. New steps in the Wnt/beta-catenin signal transduction pathway. Recent Prog Horm Res. 2000;55:225–36.
9. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.
10. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36:417–22.
11. Marques C, Ferreira JM, Andronescu E, Ficai D, Sonmez M, Ficai A. Multifunctional materials for bone cancer treatment. Int J Nanomedicine. 2014;9:2713–25.
12. Rosenberg AE. Robins and cotran pathologic basis of disease. Bone, joints and soft tissue tumors. 8th ed. Philadelphia: WB Saunders; 2010. p. 1203–56.
13. Kundu ZS. Classification, imaging, biopsy and staging of osteosarcoma. Indian J Orthop. 2014;48:238–46.
14. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.
15. Calvert GT, Randall RL, Jones KB, Cannon-Albright L, Lessnick S, Schiffman JD. At-risk populations for osteosarcoma: the syndromes and beyond. Sarcoma. 2012;2012:152382.
16. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Children’s Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:633–8.
17. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.
18. Sakamoto A. The molecular pathogenesis of dedifferentiated chondrosarcoma. Indian J Orthop. 2014;48:262–5.
19. Darouassi Y, Touati MM, Chihani M, Nadour K, Boussouga M, Ammar H, et al. Chondrosarcoma metastasis in the thyroid gland: a case report. J Med Case Rep. 2014;8:157.
20. Sridhar H, Vijaya M, Clement W, Srinivas C. Chondrosarcoma arising in an enchondroma of the metacarpal bone—a case report. J Clin Diagn Res. 2014;8:142–3.
21. Lin PP, Moussallem CD, Deavers MT. Secondary chondrosarcoma. J Am Acad Orthop Surg. 2010;18:608–15.
22. Geng S, Zhang J, Zhang LW, Wu Z, Jia G, Xiao X, et al. Diagnosis and microsurgical treatment of chondromas and chondrosarcomas of the cranial base. Oncol Lett. 2014;8:301–4.
23. Fiorenza F, Abudu A, Grimer RJ, Carter SR, Tillman RM, Ayoub K, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg (Br). 2002;84:93–9.
24. Chen B, Yang Y, Chen L, Zhou F, Yang H. Unilateral lateral mass fixation of cervical spinal low-grade chondrosarcoma with intralesional resection: a case report. Oncol Lett. 2014;7:1515–8.
25. Rossig C. Cellular immunotherapy strategies for Ewing sarcoma. Immunotherapy. 2014;6:611–21.
26. Iwamoto Y. Diagnosis and treatment of Ewing’s sarcoma. Jpn J Clin Oncol. 2007;37:79–89.
27. Cheung MR. Optimization of predictors of Ewing sarcoma cause-specific survival: a population study. Asian Pac J Cancer Prev. 2014;15:4143–5.
28. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, et al. Ewing’s sarcoma family of tumors: current management. Oncologist. 2006;11:503–19.
29. Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediate transcriptional repression via NKX2.2 during oncogenic transformation in Ewing’s sarcoma. PLoS One. 2008;3:1965.
30. Choi Y, Choi H, Jin KS, Oh JH. A case of auricular chondroma. Korean J Audiol. 2013;17:156–8.
31. Choi Y, Lim WS, Lee AY, Lee SH. Extraskeletal chondroma of the scalp: an atypical location. Indian J Dermatol Venereol Leprol. 2013;79:435–6.
32. Chung EB, Enzinger FM. Chondroma of soft parts. Cancer. 1978;41:1414–24.
33. Gungor S, Kamali G, Canat D, Gokdemir G. Soft tissue chondroma of the index finger: clinical, histological and radiological findings in a unique case. Dermatol Online J. 2013;19:18176.
34. Rabbani SA, Arakelian A, Farookhi R. LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Med. 2013;2:625–35.
35. Chu T, Teng J, Jiang L, Zhong H, Han B. Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation. Biochem Biophys Res Commun. 2014;443:962–8.
36. Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis. 2003;20:525–9.
37. Lin CH, Guo Y, Ghaffar S, McQueen P, Pourmorady J, Christ A, et al. Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma. 2013;2013:147541.
38. Cai Y, Cai T, Chen Y. Wnt pathway in osteosarcoma, from oncogenic to therapeutic. J Cell Biochem. 2014;115:625–31.
39. Lin CH, Ji T, Chen CF, Hoang BH. Wnt signaling in osteosarcoma. Adv Exp Med Biol. 2014;804:33–45.
40. Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs JJ, et al. Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun. 2013;431:274–9.
41. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009;119:837–51.
42. Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 2010;220:24–33.
43. Wan Y, Zhao W, Jiang Y, Liu D, Meng G, Cai Y. β-catenin is a valuable marker for differential diagnosis of osteoblastoma and osteosarcoma. Hum Pathol. 2014;45:1459–65.
44. Du X, Yang J, Yang D, Tian W, Zhu Z. The genetic basis for inactivation of Wnt pathway in human osteosarcoma. BMC Cancer. 2014;14:450.
45. Fanburg-Smith JC, Auerbach A, Marwaha JS, Wang Z, Rushing EJ. Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, Sox9, and osteocalcin immunostaining of 22 cases. Hum Pathol. 2010;41:653–62.
46. Uren A, Wolf V, Sun YF, Azari A, Rubin JS, Toretsky JA. Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer. 2004;43:243–9.
47. Endo Y, Beauchamp E, Woods D, Taylor WG, Toretsky JA, Uren A, et al. Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol. 2008;28:2368–79.
48. Hill TP, Später D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005;8:727–38.
49. Yuasa T, Kondo N, Yasuhara R, Shimono K, Mackem S, Pacifici M, et al. Transient activation of Wnt/{beta}-catenin signaling induces abnormal growth plate closure and articular cartilage thickening in postnatal mice. Am J Pathol. 2009;175:1993–2003.
50. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005;8:739–50.
51. Cantley L, Saunders C, Guttenberg M, Candela ME, Ohta Y, Yasuhara R, et al. Loss of β-catenin induces multifocal periosteal chondroma-like masses in mice. Am J Pathol. 2013;182:917–27.
52. Richardson RB. Age-specific bone tumour incidence rates are governed by stem cell exhaustion influencing the supply and demand of progenitor cells. Mech Ageing Dev. 2014;139C:31–40.
53. Jin S, Shen JN, Wang J, Huang G, Zhou JG. Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther. 2007;6:261–8.
54. Liu Y, Liu YZ, Zhang RX, Wang X, Meng ZJ, Huang J, et al. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Int J Oncol. 2014;45:795–803.
55. Zhang F, Chen A, Chen J, Yu T, Guo F. SiRNA-mediated silencing of beta-catenin suppresses invasion and chemosensitivity to doxorubicin in MG-63 osteosarcoma cells. Asian Pac J Cancer Prev. 2011;12:239–45.
56. Xia JJ, Pei LB, Zhuang JP, Ji Y, Xu GP, Zhang ZP, et al. Celecoxib inhibits β-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J Int Med Res. 2010;38:1294–304.
57. Leow PC, Tian Q, Ong ZY, Yang Z, Ee PL. Antitumor activity of natural compounds, curcumin and p KF118–310, as Wnt/β-catenin antagonists against human osteosarcoma cells. Investig New Drugs. 2010;28:766–82.
58. Leow PC, Bahety P, Boon CP, Lee CY, Tan KL, Yang T, et al. Functionalized curcumin analogs as potent modulators of the Wnt/β-catenin signaling pathway. Eur J Med Chem. 2014;71:67–80.
59. Liu Y, Wang W, Xu J, Li L, Dong Q, Shi Q, et al. Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Oncol Rep. 2013;30:1723–30.
60. Zeng L, Wang W, Rong XF, Zhong Y, Jia P, Zhou GQ, et al. Chondroprotective effects and multi-target mechanisms of Icariin in IL-1 beta-induced human SW 1353 chondrosarcoma cells and a rat osteoarthritis model. Int Immunopharmacol. 2014;18:175–81.
61. Fuerer C, Habib SJ, Nusse R. A study on the interactions between heparin sulfate proteoglycans and Wnt proteins. Dev Dyn. 2010;239:184–90.